Effects of Nigella sativa and its major constituent, thymoquinone on sciatic nerves in experimental diabetic neuropathy.
The aim of this study was designed to investigate the possible beneficial effects of Nigella sativa (NS) and thymoquinone (TQ) on histopathological changes of sciatic nerves in streptozotocin-induced diabetic rats. The rats were randomly allotted into one of four experimental groups: A (control), B (diabetic untreated), C (diabetic treated with NS) and D (diabetic treated with TQ); each group contain ten animals. B, C and D groups received streptozotocin (STZ) to induce diabetes. The rats in NS and TQ treated groups were given NS (in a dose of 400 mg/kg body weight) and TQ (50 mg/kg body weight) once a day orally by using intra-gastric intubation for 12 weeks starting 2 days after STZ injection, respectively. Blood and tissue samples were obtained for biochemical and histopathological investigation. The treatment of both NS and TQ caused a sharp decrease in the elevated serum glucose (P < 0.01, 0.05, respectively), and an increase in the lowered serum insulin concentrations (P < 0.01, 0.05, respectively), in STZ-induced diabetic rats. STZ induced a significant decrease in the area of insulin immunoreactive beta-cells (P < 0.0001). NS (P < 0.001) and TQ (P < 0.01) treatment resulted in increased area of insulin immunoreactive beta-cells significantly. To date, no histopathological changes of sciatic nerves in STZ induced diabetic rats by NS and TQ treatment have been reported. In this study, histologic evaluation of the tissues in diabetic animals treated with TQ and especially NS showed fewer morphologic alterations. Myelin breakdown decreased significantly after treatment with NS and TQ. The ultrastructural features of axons also showed remarkable improvement. We believe that further preclinical research into the utility of NS and TQ may indicate its usefulness as a potential treatment on peripheral neuropathy (PN) in STZ induced diabetic rats.
Kanter
Mehmet
M
Department of Histology and Embryology, Faculty of Medicine, Trakya University, Edirne, Turkey. mkanter65@yahoo.com
D000818:Animals; D016227:Benzoquinones / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D003929:Diabetic Neuropathies / Q000503:physiopathology*; D007150:Immunohistochemistry; D008297:Male; D008854:Microscopy, Electron; D031881:Nigella sativa / Q000737:chemistry*; D051381:Rats; D012584:Sciatic Nerve / Q000187:drug effects* / Q000503:physiopathology / Q000648:ultrastructure; D013311:Streptozocin
D016227:Benzoquinones; D013311:Streptozocin; C003466:thymoquinone
Free Radic Biol Med. 2001 Feb 1;30(3):232-7
11165869
Biochem Soc Trans. 2003 Dec;31(Pt 6):1423-5
14641079
J Biol Chem. 1997 Jan 3;272(1):601-8
8995303
J Histochem Cytochem. 1981 Apr;29(4):577-80
6166661
Diabet Med. 1986 Jul-Aug;3(4):330-4
2949921
Altern Med Rev. 2006 Dec;11(4):294-329
17176168
Res Vet Sci. 2005 Dec;79(3):219-23
16054891
Diabetes Care. 1992 Mar;15(3):442-55
1559411
World J Gastroenterol. 2005 Nov 14;11(42):6684-8
16425366
Diabetes. 1977 Jul;26(7):689-92
141385
Horm Metab Res. 1982 Jan;14(1):10-3
6460676
Diabetes Care. 1990 Jun;13(6):610-30
2192847
J Ethnopharmacol. 1991 Sep;34(2-3):275-8
1795532
Diabetologia. 1993 Apr;36(4):299-304
8477873
Drugs Aging. 1996 Aug;9(2):69-77
8820792
J Neurol Neurosurg Psychiatry. 1979 Jun;42(6):509-18
469558
Cancer Chemother Rep. 1963 May;29:91-8
13990586
Environ Health Perspect. 1997 Sep;105 Suppl 5:1127-30
9400711
Anat Rec A Discov Mol Cell Evol Biol. 2004 Jul;279(1):685-91
15224410
Diabetologia. 1998 Apr;41(4):390-9
9562342
J Biol Chem. 1998 Feb 6;273(6):3756-64
9452508
Trends Pharmacol Sci. 1994 Aug;15(8):293-7
7940997
Arch Toxicol. 2006 Apr;80(4):217-24
16240107
Biochem J. 1963 Jul;88:137-46
13952078
J Neurosci. 1998 Feb 1;18(3):830-40
9437005
Diabetologia. 1997 Mar;40(3):271-81
9084964
Res Vet Sci. 2002 Dec;73(3):279-82
12443686
World J Gastroenterol. 2005 Nov 14;11(42):6662-6
16425361
Metabolism. 1998 May;47(5):578-83
9591750
Diabetes. 2003 Aug;52(8):2110-20
12882930
Therapie. 2000 May-Jun;55(3):379-82
10967716
Biochem Med. 1980 Apr;23(2):231-5
6893150
Arch Toxicol. 2006 Nov;80(11):768-76
16609887
Brain. 1984 Sep;107 ( Pt 3):935-50
6478183
Diabetes. 1991 Apr;40(4):405-12
2010041
Pancreas. 1993 Jan;8(1):50-7
8419909
Tohoku J Exp Med. 2003 Dec;201(4):213-9
14690013
J Neurol Sci. 1985 Mar;67(3):285-97
3989572
Hum Exp Toxicol. 2006 Mar;25(3):127-33
16634331
Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S201-7
8529515
Biochem Mol Biol Int. 1993 Aug;30(6):1035-41
8220250
Biochem Pharmacol. 1973 Oct 15;22(20):2625-31
4357891
Gen Pharmacol. 1993 Sep;24(5):1115-22
8270170
Science. 1954 Nov 19;120(3125):841-3
13216176
J Biol Chem. 1999 Feb 19;274(8):5038-46
9988750
Can J Physiol Pharmacol. 1997 Dec;75(12):1356-61
9534946
Exp Clin Endocrinol Diabetes. 2001;109(6):330-6
11571671
Clin Chem. 1977 Jan;23(1):131-9
832363
Diabetologia. 1996 Feb;39(2):172-82
8635669
Acta Physiol Hung. 1997-1998;85(1):29-38
9530434
Brain. 1989 Feb;112 ( Pt 1):197-208
2521806
Clin Exp Pharmacol Physiol. 2006 Dec;33(12 ):1231-8
17184506
Br Med J. 1976 Jul 31;2(6030):278-9
133745
Planta Med. 1995 Feb;61(1):33-6
7700988
Eur J Pharmacol. 2006 Jan 13;530(1-2):48-53
16359659
Prostaglandins Leukot Essent Fatty Acids. 1988;31(3):181-97
3047752
Med Hypotheses. 1989 May;29(1):47-50
2664434
Ann Intern Med. 1995 Apr 15;122(8):561-8
7887548
Exp Diabesity Res. 2004 Jan-Mar;5(1):37-50
15198370
Diabetologia. 1994 May;37(5):449-59
8056181